(Z)-(R)-N-(2-((3-((1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)amino)-2-oxo-1-phenylethyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamid

ID: ALA3823844

Chembl Id: CHEMBL3823844

PubChem CID: 124126397

Max Phase: Preclinical

Molecular Formula: C33H24F2N6O4

Molecular Weight: 606.59

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  O=C1Nc2ccc(NC(=O)[C@H](NC(=O)c3cccn(Cc4ccc(F)c(F)c4)c3=O)c3ccccc3)cc2/C1=C/c1cnc[nH]1

Standard InChI:  InChI=1S/C33H24F2N6O4/c34-26-10-8-19(13-27(26)35)17-41-12-4-7-23(33(41)45)30(42)40-29(20-5-2-1-3-6-20)32(44)38-21-9-11-28-24(14-21)25(31(43)39-28)15-22-16-36-18-37-22/h1-16,18,29H,17H2,(H,36,37)(H,38,44)(H,39,43)(H,40,42)/b25-15-/t29-/m1/s1

Standard InChI Key:  XCPMMIISBZJPHR-OXTLUBNBSA-N

Alternative Forms

1. Parent:

   

   ALA3823844

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 606.59

Molecular Weight (Monoisotopic): 606.1827

AlogP: 4.50

#Rotatable Bonds: 8

Polar Surface Area: 137.98

Molecular Species: NEUTRAL

HBA: 6

HBD: 4

#RO5 Violations: 1

HBA (Lipinski): 10

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 11.03

CX Basic pKa: 6.64

CX LogP: 3.20

CX LogD: 3.15

Aromatic Rings: 5

Heavy Atoms: 45

QED Weighted: 0.19

Np Likeness Score: -1.50

References

1. Sestito S, Daniele S, Nesi G, Zappelli E, Di Maio D, Marinelli L, Digiacomo M, Lapucci A, Martini C, Novellino E, Rapposelli S..  (2016)  Locking PDK1 in DFG-out conformation through 2-oxo-indole containing molecules: Another tools to fight glioblastoma.,  118  [PMID:27123901] [10.1016/j.ejmech.2016.04.003]

2. Sestito S, Bacci A, Chiarugi S, Runfola M, Gado F, Margheritis E, Gul S, Riveiro ME, Vazquez R, Huguet S, Manera C, Rezai K, Garau G, Rapposelli S..  (2021)  Development of potent dual PDK1/AurA kinase inhibitors for cancer therapy: Lead-optimization, structural insights, and ADME-Tox profile.,  226  [PMID:34624821] [10.1016/j.ejmech.2021.113895]

3. Thakur A, Faujdar C, Sharma R, Sharma S, Malik B, Nepali K, Liou JP..  (2022)  Glioblastoma: Current Status, Emerging Targets, and Recent Advances.,  65  (13.0): [PMID:35786935] [10.1021/acs.jmedchem.1c01946]

4. Dhokne P, Sakla AP, Shankaraiah N..  (2021)  Structural insights of oxindole based kinase inhibitors as anticancer agents: Recent advances.,  216  [PMID:33721669] [10.1016/j.ejmech.2021.113334]

5. Liu M, Ju X, Zou J, Shi J, Jia G..  (2020)  Recent researches for dual Aurora target inhibitors in antitumor field.,  203  [PMID:32693295] [10.1016/j.ejmech.2020.112498]

Source

Source(1):

• Scientific Literature